What special market exclusivity period does the FDA grant to approved orphan drugs in the US, creating a significant pricing advantage for pharmaceutical companies?

Orphan drugs treat rare diseases affecting small patient populations. Despite their limited market, these medications often come with eye-watering price tags. This poll explores the fascinating economics behind orphan drug pricing in the pharmaceutical industry, where development costs, market exclusivity, and ethical considerations create a complex pricing landscape that differs dramatically from standard pharmaceutical products.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

7 years of market exclusivity, regardless of patent status
3 years of market exclusivity, with potential for 2-year extension
10 years of market exclusivity, but only for conditions affecting fewer than 10,000 patients
5 years of market exclusivity, with mandatory price controls after that period